Latest News

To participate to World Hepatitis Day campaign, please create your own poster using this link and send it to info@ice-hbv.org or tweet @ICE_HBV

2-2:45pm – Session 1 – Vaccines – the Most Effective Route to Elimination?

Co-Chairs: Peter Revill (Doherty Institute) and Helen Tyrell (Hepatitis Australia)

• Hepatitis C Vaccines– Heidi Drummer – Burnet Institute
• Hepatitis B Vaccines – Tilman Ruff – University of Melbourne

2:45-3:45pm – Session 2 – Test & Treat – Update and Challenges to Roll-Out

Co-Chairs: Mike Catton (Doherty Institute) and Melanie Eagle (Hepatitis Victoria)

• New HBV Treatment Strategies – Renae Walsh – Doherty Institute 
• Viral Hepatitis – Laboratory Networks and Capacity in Mongolia -Suellen Nicholson-  Doherty Institute 
• Regional implementation of the Global Health Sector Strategy for Viral Hepatitis – Laura Thomas– Doherty Institute 
• CHB in Australia – Domestic Progress Report –  Jennifer MacLachlan – Doherty Institute 

4:00-4:45pm – Session 3 – HBV & Migrants 

Chair: Benjamin Cowie (Doherty Institute)

• Hepatitis B and Migrants, Lachlan Riches – Migration and Legal Consultant 
• HBV & Migration, a patient experience, Lien Tran – Hepatitis Victoria (pictured below)

4:50-5:45pm – Session 4 – Global Collaborations to Cure CHB 

Chair: Anne Kelso (NHMRC)

•  The path towards the cure of HBV infection –  Fabien Zoulim – ANRS, France
• HBV clinical studies in the Asia-Pacific Region – Seng Gee Lim  – National University Health System, Singapore

5:45-6:00pm – Session 5 – Progress made in the roll-out of Victoria viral hepatitis strategies , The Honorable Frank McGuire, Parliamentary Secretary for Medical research

Sponsors:

In collaboration with:

General Abstracts

• General abstract submission deadline is Monday, June 26, 2017.
• Participants will be notified on Monday, July 24, 2017 of their inclusion in the program.
• At least one author must be registered for the meeting in order for an abstract to be included in the program book.

http://www.hbvmeeting.org/abstracts-and-travel-grants/abstract-submission/

ICE-HBV and the WHO Collaborating Centre for Viral Hepatitis at the Peter Doherty Institute for Infection and Immunity are organising a World Hepatitis Day symposium entitled From Vaccine to Cure: The Road to Viral Hepatitis Elimination.

Join us on 28 July from 2pm to 6pm, in person or online via Zoom. Please register here: https://goo.gl/2noLVa (free). Check the preliminary programme.

To participate to World Hepatitis Day campaign which will be displayed during the event, please create your own poster using this link and send it to info@ice-hbv.org or tweet @ICE_HBV

All events related to World Hepatitis Day in Victoria can be found on Hepatitis Victoria website.

Sponsors:

In collaboration with:

ICE-HBV manifesto was selected as one of the 180 scientific findings published in 2016 that editors believe could have the greatest impact on society’s most pressing problems.

It is free-access until the end of July on:

https://goo.gl/j3Ua6S

Following ICE-HBV’s request to Anthony Fauci to consider strengthening HBV research programmes and subsequent discussions, we received the following statement from John J. McGowan, Ph.D., Deputy Director for Science Management at NIAID:

We at the National Institute of Allergy and Infectious Diseases (NIAID) agree that chronic hepatitis B infection remains a major problem globally.  In the United States as well as in other developed and developing countries, too few are vaccinated.  The result is that millions with chronic disease will require treatment to prevent end-stage liver disease, cancer and an early death.  NIAID supports a broad hepatitis B research portfolio, including basic research supported through R01 and R21 grants, drug and animal model development through small business grants, and the availability of a comprehensive array of preclinical services.  In addition, NIAID has a current initiative PAR-14-255 (Multidisciplinary Studies of HIV and Viral Hepatitis Co-infection) with a final receipt date in May of 2017.  NIAID also has two new concepts that were approved by the NIAID Advisory Council in January 2017:

• HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research – R01 and R21
• In Vitro and Animal Model Studies on HBV/HIV Co-Infection – R01 and R21

You also should be aware of the SBIR initiative launched by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) entitled “New Technologies for Viral Hepatitis SBIR (R43/R44)”.

(NIAID staff) will continue to work with you to address the challenges we face as a community.

ICE-HBV Governing Board will keep approaching research institutes and foundations to request a scaling-up of HBV research programmes worldwide.

http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/